Aptamer Complement Inhibitor is a synthetic oligonucleotide-based binding molecule that selectively targets and modulates specific components of the complement system to inhibit aberrant immune activation, distinguished by its high-affinity, nucleic acid-based structure engineered through systematic evolution of ligands by exponential enrichment (SELEX).
3
Publications
180
Citations
17
Authors
6
Institutions
Publications per year
2017–2026
1
Parents
Publications
3
Derivation of RNA aptamer inhibitors of human complement C5
G Biesecker, Larry Dihel, Kristin Enney et al. · Immunopharmacology · 1999 · 150 citations
RNA Aptamer Therapy for Vaso-Occlusion in Sickle Cell Disease
Angela D. Burnette, Shahid M. Nimjee, Milena Batchvarova et al. · Nucleic Acid Therapeutics · 2011 · 15 citations
1–3 of 3
Authors
17
- AD
1
h-index
- JN
1
h-index
- DT
1
h-index
- GB
1
h-index
- DW
1
h-index
1–5 of 17
Institutions
6
The University of Osaka
Osaka, Japan
1 h-index
1 publications
15 citations
Kansas State University
Manhattan, United States
1 h-index
3 publications
45 citations
Wesleyan University
Middletown, United States
1 h-index
1 publications
15 citations
Nivalis Therapeutics (United States)
Boulder, United States
1 h-index
1 publications
150 citations
Duke Medical Center
Durham, United States
1 h-index
6 publications
90 citations
SomaLogic (United States)
Boulder, United States
1 h-index
2 publications
30 citations
1–6 of 6
Venues
- The Journal of Immunology
JI · 1 publications · 15 citations
1
h-index
- Nucleic Acid Therapeutics
1 publications · 15 citations
1
h-index
- Immunopharmacology
1 publications · 150 citations
1
h-index
1–3